Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy

• Status: Completed
• Trial end date: 2003-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose: There are some controversies about the effect of Levodopa-Carbidopa on treatment of non-arteritic anterior ischemic optic neuropathy (NAION). This study was performed to evaluate the effect of Levodopa-Carbidopa on visual acuity, color vision, and visual field in patients with recent onset NAION (less than 6 weeks duration).

Patients and Methods: In this double-blind randomized clinical trial, 13 patients were treated with levodopa-carbidopa and 12 patients took placebo for 3 weeks. Visual acuity, color vision, and visual field were tested before and at 4th, 12th, 16th, and 24th weeks after enrollment, and evaluated.

• Phase: Phase 4

Details

• Lead Sponsor: Shahid Beheshti University of Medical Sciences
• Treatments: Carbidopa; Carbidopa, levodopa drug combination; Levodopa

Criteria

Inclusion Criteria:

• age greater than 50 years old

• first ophthalmic examination within 6 weeks after onset of disease

• presence of optic disc swelling followed by optic atrophy within 6 weeks

• altitudinal, central or generalized visual field defect

• normal ESR

Exclusion Criteria:

• confirmed giant cell arteritis

• history of any ocular surgeries

• optic neuropathy due to acute bleeding

• advanced diabetic retinopathy

• uncontrolled glaucoma

• any ocular disorders that cause visual acuity reduction rather than NAION